Phase 2 Clinical Trial study using Bevacizumab plus irinotecan stabilized disease progression in a cohort of children with progressive, low-grade glioma.

“Bevacizumab either alone or in combination can be used as one of the therapeutic approaches for children with recurrent low-grade glioma and may help to defer or avoid radiotherapy, especially in young children,” Sridharan Gururangan, MRCP, professor of pediatrics, associate professor of surgery and director of pediatric clinical services at The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, told HemOnc Today. “This treatment regimen appears to be reasonably well tolerated as well in these children, although the impact of bevacizumab on linear growth — especially in young children — is unknown…”

Read full article at